Oramed Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Oramed Pharmaceuticals has a total shareholder equity of $162.9M and total debt of $51.0M, which brings its debt-to-equity ratio to 31.3%. Its total assets and total liabilities are $220.6M and $57.7M respectively.
Key information
31.3%
Debt to equity ratio
US$51.01m
Debt
Interest coverage ratio | n/a |
Cash | US$162.05m |
Equity | US$162.89m |
Total liabilities | US$57.66m |
Total assets | US$220.55m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ORMP's short term assets ($162.6M) exceed its short term liabilities ($53.2M).
Long Term Liabilities: ORMP's short term assets ($162.6M) exceed its long term liabilities ($4.4M).
Debt to Equity History and Analysis
Debt Level: ORMP has more cash than its total debt.
Reducing Debt: ORMP's debt to equity ratio has increased from 0% to 31.3% over the past 5 years.
Debt Coverage: ORMP's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ORMP's interest payments on its debt are well covered by EBIT.